REPLIGEN CORP Net Income (Loss) Attributable to Parent, Diluted
REPLIGEN CORP (RGEN) reported Net Income (Loss) Attributable to Parent, Diluted of -$25.51 million for the 12-month period ending 2024-12-31, per its 10-K filed 2025-03-14.
Financial Statements › Income Statement › Net Income
us-gaap:NetIncomeLossAttributableToParentDiluted · last filed 2025-03-14
- REPLIGEN CORP net income (loss) attributable to parent, diluted for the quarter ending 2023-12-31 was -$16.45M, a 133.76% decline year-over-year.
- REPLIGEN CORP net income (loss) attributable to parent, diluted for the quarter ending 2023-09-30 was $16.92M, a 58.12% decline year-over-year.
- REPLIGEN CORP net income (loss) attributable to parent, diluted for the quarter ending 2023-06-30 was $19.79M, a 60.32% decline year-over-year.
- REPLIGEN CORP net income (loss) attributable to parent, diluted for the quarter ending 2023-03-31 was $15.34M, a 67.61% decline year-over-year.
- REPLIGEN CORP net income (loss) attributable to parent, diluted for fiscal 2024 was -$25.51M, a 171.68% decline from fiscal 2023.
- REPLIGEN CORP net income (loss) attributable to parent, diluted for fiscal 2023 was $35.60M, a 80.90% decline from fiscal 2022.
- REPLIGEN CORP net income (loss) attributable to parent, diluted for fiscal 2022 was $186.35M, a 45.25% increase from fiscal 2021.
- REPLIGEN CORP net income (loss) attributable to parent, diluted for fiscal 2021 was $128.29M, a 114.08% increase from fiscal 2020.
| Period end | Net Income (Loss) Attributable to Parent, Diluted 3 month | Net Income (Loss) Attributable to Parent, Diluted 3 month as first filed | Net Income (Loss) Attributable to Parent, Diluted 6 month | Net Income (Loss) Attributable to Parent, Diluted 6 month as first filed | Net Income (Loss) Attributable to Parent, Diluted 9 month | Net Income (Loss) Attributable to Parent, Diluted 9 month as first filed | Net Income (Loss) Attributable to Parent, Diluted 12 month | Net Income (Loss) Attributable to Parent, Diluted 12 month as first filed |
|---|---|---|---|---|---|---|---|---|
| 2024-12-31 | -$25.51M 10-K · filed 2025-03-14 | |||||||
| 2023-12-31 | -$16.45M derived: 10-K 12 month − 10-Q/A 9 month · filed 2025-03-14 | $473.00K derived: sum of 2 quarters · filed 2025-03-14 | $20.26M derived: sum of 3 quarters · filed 2025-03-14 | $35.60M 10-K · filed 2025-03-14 | $41.58M 10-K · filed 2024-02-22 | |||
| 2023-09-30 | $16.92M 10-Q/A · filed 2024-11-18 | $18.17M 10-Q · filed 2023-10-31 | $36.71M derived: sum of 2 quarters · filed 2024-11-18 | $52.05M 10-Q/A · filed 2024-11-18 | $67.06M 10-Q · filed 2023-10-31 | $100.78M derived: sum of 4 quarters · filed 2025-03-14 | ||
| 2023-06-30 | $19.79M 10-Q/A · filed 2024-11-18 | $20.06M 10-Q · filed 2023-08-02 | $35.12M 10-Q/A · filed 2024-11-18 | $48.89M 10-Q · filed 2023-08-02 | $83.85M derived: sum of 3 quarters · filed 2025-03-14 | $124.26M derived: sum of 4 quarters · filed 2025-03-14 | ||
| 2023-03-31 | $15.34M 10-Q/A · filed 2024-11-18 | $28.83M 10-Q · filed 2023-05-02 | $64.07M derived: sum of 2 quarters · filed 2025-03-14 | $104.47M derived: sum of 3 quarters · filed 2025-03-14 | $154.33M derived: sum of 4 quarters · filed 2025-03-14 | |||
| 2022-12-31 | $48.73M derived: 10-K 12 month − 10-Q/A 9 month · filed 2025-03-14 | $89.13M derived: sum of 2 quarters · filed 2025-03-14 | $139.00M derived: sum of 3 quarters · filed 2025-03-14 | $186.35M 10-K · filed 2025-03-14 | ||||
| 2022-09-30 | $40.41M 10-Q/A · filed 2024-11-18 | $90.27M derived: sum of 2 quarters · filed 2024-11-18 | $137.62M 10-Q/A · filed 2024-11-18 | $166.73M derived: sum of 4 quarters · filed 2024-11-18 | ||||
| 2022-06-30 | $49.86M 10-Q/A · filed 2024-11-18 | $97.21M 10-Q/A · filed 2024-11-18 | $126.32M derived: sum of 3 quarters · filed 2024-11-18 | $159.82M derived: sum of 4 quarters · filed 2024-11-18 | ||||
| 2022-03-31 | $47.35M 10-Q/A · filed 2024-11-18 | $29.45M 10-Q · filed 2022-04-27 | $76.46M derived: sum of 2 quarters · filed 2024-11-18 | $109.96M derived: sum of 3 quarters · filed 2024-11-18 | $146.19M derived: sum of 4 quarters · filed 2024-11-18 | |||
| 2021-12-31 | $29.11M derived: 10-K/A 12 month − 10-Q 9 month · filed 2024-11-18 | $62.61M derived: sum of 2 quarters · filed 2024-11-18 | $98.84M derived: sum of 3 quarters · filed 2024-11-18 | $128.29M 10-K/A · filed 2024-11-18 | ||||
| 2021-09-30 | $33.50M 10-Q · filed 2022-11-01 | $69.73M derived: sum of 2 quarters · filed 2022-11-01 | $99.18M 10-Q · filed 2022-11-01 | |||||
| 2021-06-30 | $36.23M 10-Q · filed 2022-08-02 | $65.68M 10-Q · filed 2022-08-02 | ||||||
| 2021-03-31 | $47.35M 10-Q · filed 2022-04-27 | |||||||
| 2020-12-31 | $59.93M 10-K · filed 2023-02-22 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Krystal Biotech, Inc. (KRYS) | United States | $10.210B | 45.56 |
| BIO-TECHNE Corp (TECH) | United States | $11.379B | 74.68 |
| Twist Bioscience Corp (TWST) | United States | $11.540B | -47.21 |
| Kymera Therapeutics, Inc. (KYMR) | United States | $9.631B | -31.69 |
| ImmunityBio, Inc. (IBRX) | United States | $9.157B | -9.29 |
| Vaxcyte, Inc. (PCVX) | United States | $8.466B | -7.91 |
| HALOZYME THERAPEUTICS, INC. (HALO) | United States | $13.083B | 21.59 |
| NEUROCRINE BIOSCIENCES INC (NBIX) | United States | $14.131B | 24.25 |
| EXELIXIS, INC. (EXEL) | United States | $14.358B | 16.15 |
| Immunovant, Inc. (IMVT) | United States | $7.028B | -14.78 |